SJS
MCID: SVR097
MIFTS: 69

Severe Cutaneous Adverse Reaction (SJS)

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Severe Cutaneous Adverse Reaction

MalaCards integrated aliases for Severe Cutaneous Adverse Reaction:

Name: Severe Cutaneous Adverse Reaction 58 39 17
Stevens-Johnson Syndrome 58 39 12 77 60 76 56 6 45 15 17 74
Toxic Epidermal Necrolysis 58 60 76 56 6 17 74
Susceptibility to Severe Cutaneous Adverse Reaction 30 6 41
Hypersensitivity Syndrome, Carbamazepine-Induced, Susceptibility to 58 13
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 74
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum 60
Severe Cutaneous Adverse Reaction, Susceptibility to 58
Hypersensitivity Syndrome, Carbamazepine-Induced 58
Toxic Epidermal Necrolysis, Susceptibility to 58
Stevens-Johnson Syndrome, Susceptibility to 58
Dermatostomatitis, Stevens Johnson Type 60
Dermatostomatitis Stevens Johnson Type 76
Drug-Induced Stevens Johnson Syndrome 74
Toxic Epidermolysis 60
Lyell Syndrome 60
Sjs-Ten 60
Sjs 76
Ten 76

Characteristics:

Orphanet epidemiological data:

60
toxic epidermal necrolysis
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome/toxic epidermal necrolysis spectrum
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 60  
Rare skin diseases


Summaries for Severe Cutaneous Adverse Reaction

UniProtKB/Swiss-Prot : 76 Stevens-Johnson syndrome: A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

MalaCards based summary : Severe Cutaneous Adverse Reaction, also known as stevens-johnson syndrome, is related to stevens-johnson syndrome/toxic epidermal necrolysis and hematopoietic stem cell transplantation. An important gene associated with Severe Cutaneous Adverse Reaction is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Stavudine and Nevirapine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are dysphagia and nausea and vomiting

Disease Ontology : 12 A skin disease that is characterized by ulceration of less than 10 percent of the surface area of the body. The disease is often precipitated by the use of medications, such as antibiotics or antiepileptics, or onset of infection.

Wikipedia : 77 Stevens–Johnson syndrome (SJS) is a type of severe skin reaction. Together with toxic epidermal... more...

Description from OMIM: 608579

Related Diseases for Severe Cutaneous Adverse Reaction

Diseases related to Severe Cutaneous Adverse Reaction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 stevens-johnson syndrome/toxic epidermal necrolysis 32.0 FAS HLA-A HLA-B HLA-C IKZF1 PSORS1C1
2 hematopoietic stem cell transplantation 30.7 HLA-A HLA-B HLA-C
3 paraneoplastic pemphigus 30.6 HLA-A HLA-B HLA-C
4 herpes zoster 30.5 HCP5 HLA-A HLA-B
5 graft-versus-host disease 30.4 FAS FASLG GZMB HLA-A HLA-B HLA-C
6 cytomegalovirus infection 30.4 FAS HLA-A HLA-B
7 aplastic anemia 30.1 FAS FASLG HLA-A HLA-B PRF1
8 hemophagocytic lymphohistiocytosis 29.9 FAS GNLY GZMB PRF1
9 schwartz-jampel syndrome, type 1 12.3
10 ritter's disease 11.8
11 sjogren syndrome 11.4
12 5-oxoprolinase deficiency 11.4
13 auditory neuropathy spectrum disorder 11.4
14 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 11.1
15 swyer-james syndrome 11.1
16 lupus erythematosus 10.7
17 ocular cicatricial pemphigoid 10.5
18 cutaneous lupus erythematosus 10.5
19 herpes simplex 10.5
20 phenytoin or carbamazepine toxicity 10.5 HLA-A HLA-B
21 systemic lupus erythematosus 10.5
22 fixed drug eruption 10.5
23 cataract 10.4
24 postherpetic neuralgia 10.4 HLA-A HLA-B
25 atrial tachyarrhythmia with short pr interval 10.4 HLA-A HLA-B
26 htlv-1 associated myelopathy/tropical spastic paraparesis 10.4 HLA-A HLA-B
27 conjunctivitis 10.4
28 influenza 10.4
29 caplan's syndrome 10.4 FAS HLA-A
30 breast medullary carcinoma 10.3 FASLG GZMB
31 chronic venous leg ulcers 10.3 FAS FASLG
32 lymphoma 10.3
33 dermatitis 10.3
34 purpura 10.3
35 pars planitis 10.3 HLA-A HLA-B
36 type ii mixed cryoglobulinemia 10.3 FAS FASLG
37 lymphocytic gastritis 10.3 FAS FASLG GZMB
38 endophthalmitis 10.3
39 measles 10.3
40 autoimmune progesterone dermatitis 10.3
41 lymphomatoid papulosis 10.3 FAS FASLG GZMB
42 vogt-koyanagi-harada disease 10.3 FAS HLA-A HLA-B
43 choriocarcinoma of the testis 10.3 FASLG GZMB
44 myeloma, multiple 10.3
45 contact dermatitis 10.3
46 acquired immunodeficiency syndrome 10.3
47 psoriasis 10.3
48 pemphigus 10.3
49 granulocytopenia 10.3
50 anterior uveitis 10.3 HLA-A HLA-B

Graphical network of the top 20 diseases related to Severe Cutaneous Adverse Reaction:



Diseases related to Severe Cutaneous Adverse Reaction

Symptoms & Phenotypes for Severe Cutaneous Adverse Reaction

Human phenotypes related to Severe Cutaneous Adverse Reaction:

60 33 (show all 50)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 60 33 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0002015
2 nausea and vomiting 60 33 hallmark (90%) Occasional (29-5%),Very frequent (99-80%) HP:0002017
3 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
4 polydipsia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001959
5 fatigue 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012378
6 abnormal blistering of the skin 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0008066
7 weight loss 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001824
8 thrombocytopenia 60 33 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0001873
9 diarrhea 60 33 hallmark (90%) Very frequent (99-80%) HP:0002014
10 erythema 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0010783
11 macule 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012733
12 neutropenia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001875
13 sepsis 60 33 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0100806
14 acantholysis 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0100792
15 recurrent respiratory infections 60 33 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002205
16 malabsorption 60 33 frequent (33%) Frequent (79-30%) HP:0002024
17 anemia 60 33 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0001903
18 abdominal pain 60 33 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002027
19 cough 60 33 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0012735
20 abnormality of neutrophils 60 33 frequent (33%) Frequent (79-30%) HP:0001874
21 dysuria 60 33 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0100518
22 excessive salivation 60 33 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0003781
23 elevated hepatic transaminase 33 occasional (7.5%) HP:0002910
24 sudden cardiac death 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001645
25 visual impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0000505
26 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000083
27 photophobia 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000613
28 dyspnea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002094
29 myocardial infarction 60 33 occasional (7.5%) Occasional (29-5%) HP:0001658
30 respiratory distress 60 33 occasional (7.5%) Occasional (29-5%) HP:0002098
31 corneal erosion 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0200020
32 abnormality of the pleura 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002103
33 skin ulcer 60 33 occasional (7.5%) Occasional (29-5%) HP:0200042
34 pancreatitis 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001733
35 abnormal myocardium morphology 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001637
36 visual loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0000572
37 gastrointestinal hemorrhage 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002239
38 conjunctivitis 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000509
39 acute hepatic failure 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0006554
40 tracheoesophageal fistula 60 33 occasional (7.5%) Occasional (29-5%) HP:0002575
41 abnormality of the urethra 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000795
42 dyspareunia 60 33 occasional (7.5%) Occasional (29-5%) HP:0030016
43 restrictive ventilatory defect 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002091
44 entropion 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000621
45 intestinal perforation 60 33 occasional (7.5%) Occasional (29-5%) HP:0031368
46 esophageal stricture 60 33 occasional (7.5%) Occasional (29-5%) HP:0002043
47 hypokalemic metabolic alkalosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001960
48 abnormal vagina morphology 33 occasional (7.5%) HP:0000142
49 elevated hepatic transaminases 60 Frequent (79-30%),Occasional (29-5%)
50 abnormality of the vagina 60 Occasional (29-5%)

Clinical features from OMIM:

608579

GenomeRNAi Phenotypes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

27 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.34 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.34 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.34 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.34 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.34 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.34 HLA-A HLA-B HLA-C PRF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.34 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.34 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.34 HLA-A HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.34 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.34 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.34 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.34 PRF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.34 PRF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.34 PRF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.34 HLA-A HLA-B HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.34 HLA-A HLA-B HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.34 HLA-C

MGI Mouse Phenotypes related to Severe Cutaneous Adverse Reaction:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.23 FAS FASLG HSPG2 IKZF1 NFKBIZ PRF1

Drugs & Therapeutics for Severe Cutaneous Adverse Reaction

Drugs for Severe Cutaneous Adverse Reaction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
2
Nevirapine Approved Phase 4 129618-40-2 4463
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
6
leucovorin Approved Phase 4 58-05-9 6006 143
7
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
8
Pantoprazole Approved Phase 4 102625-70-7 4679
9
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
11 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
12 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
14 Antiviral Agents Phase 4,Phase 2
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
17 Cytochrome P-450 CYP3A Inducers Phase 4
18 Anti-Retroviral Agents Phase 4,Phase 2
19 Reverse Transcriptase Inhibitors Phase 4,Phase 2
20 Anti-HIV Agents Phase 4,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 3
22 Antifungal Agents Phase 4,Phase 3
23 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Cyclosporins Phase 4,Phase 3
25 Immunologic Factors Phase 4,Phase 3,Not Applicable
26 Immunosuppressive Agents Phase 4,Phase 3,Not Applicable
27 Vaccines Phase 4,Phase 3,Not Applicable
28 Antiparasitic Agents Phase 4
29 Anti-Infective Agents, Urinary Phase 4
30 Folate Phase 4,Phase 1,Phase 2
31 Vitamin B9 Phase 4,Phase 1,Phase 2
32 Folic Acid Antagonists Phase 4
33 Antiprotozoal Agents Phase 4
34 Renal Agents Phase 4
35 Vitamin B Complex Phase 4,Phase 1,Phase 2
36 Antimalarials Phase 4
37 Fanasil, pyrimethamine drug combination Phase 4
38 Anti-Ulcer Agents Phase 4
39 Proton Pump Inhibitors Phase 4
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Antacids Phase 4
42
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
43
Linagliptin Approved Phase 3 668270-12-0 10096344
44
Insulin glargine Approved Phase 3 160337-95-1
45
Zinc Approved, Investigational Phase 3 7440-66-6 32051
46
Dulaglutide Approved, Investigational Phase 3 923950-08-7
47
Insulin Lispro Approved Phase 3 133107-64-9
48
Valproic Acid Approved, Investigational Phase 3 99-66-1 3121
49
Lamotrigine Approved, Investigational Phase 3,Phase 2 84057-84-1 3878
50
Etanercept Approved, Investigational Phase 3,Not Applicable 185243-69-0

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
2 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
3 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
4 IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda Completed NCT00372632 Phase 4 Sulfadoxine-Pyrimethamine;placebo
5 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
6 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
8 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed NCT01621178 Phase 3 Dulaglutide;Insulin glargine;Insulin lispro
9 Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
10 Clinical Evaluation of BW430C in Epilepsy Completed NCT00395694 Phase 3 lamictal
11 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Completed NCT00346450 Phase 3
12 Aloe Vera on Irradiated Breast Tissue Completed NCT01824134 Phase 3
13 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
14 Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide Recruiting NCT03298802 Phase 3 Hydrochlorothiazide 50mg Tablet;Placebo Tablet
15 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
16 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Terminated NCT00858364 Phase 3 Darbepoetin alfa;Placebo
17 Lamictal in the Treatment of Post-Herpetic Neuralgia Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
19 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
20 Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency Unknown status NCT00845117 Phase 1, Phase 2
21 Utilization of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Healing Completed NCT02746848 Phase 1, Phase 2
22 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
23 A Study of LY2484595 in Japanese Subjects Completed NCT01375075 Phase 2 LY2484595;Placebo;Atorvastatin
24 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
25 Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study Recruiting NCT02229123 Phase 2 Intravenous Levetiracetam
26 A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies Recruiting NCT02494986 Phase 2 Rilpivirine
27 Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Active, not recruiting NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
28 Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
29 Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
30 Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
31 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
32 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
33 PRF in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
34 HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Unknown status NCT03046914 Not Applicable
35 Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
36 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions Completed NCT01276314 Not Applicable anti- TNF-a;Prednisolone
37 Stevens-Johnson Syndrome Antimicrobial Completed NCT00844038
38 Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242 Not Applicable
39 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Completed NCT00357071
40 Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Completed NCT02945176 Not Applicable
41 Perioperative Research Into Memory: Cognitive Outcome Following Major Burns Completed NCT03470844
42 Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT Completed NCT02261506 Not Applicable
43 Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections Completed NCT02311452
44 Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments Completed NCT01086319
45 Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268) Completed NCT01078246
46 Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration Completed NCT00460408 Macugen
47 Severe Cutaneous Adverse Reactions in Thailand Recruiting NCT02574988
48 Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Recruiting NCT03176342 Not Applicable
49 An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Recruiting NCT03659227

Search NIH Clinical Center for Severe Cutaneous Adverse Reaction

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Severe Cutaneous Adverse Reaction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Severe Cutaneous Adverse Reaction:
Cultivated corneal epithelial stem cells for treatment of ocular surface damage
Embryonic/Adult Cultured Cells Related to Severe Cutaneous Adverse Reaction:
Limbal corneal epithelial stem cells PMIDs: 23055668

Cochrane evidence based reviews: stevens-johnson syndrome

Genetic Tests for Severe Cutaneous Adverse Reaction

Genetic tests related to Severe Cutaneous Adverse Reaction:

# Genetic test Affiliating Genes
1 Susceptibility to Severe Cutaneous Adverse Reaction 30 HLA-A HLA-B

Anatomical Context for Severe Cutaneous Adverse Reaction

MalaCards organs/tissues related to Severe Cutaneous Adverse Reaction:

42
Skin, Eye, T Cells, Salivary Gland, Testes, Kidney, Neutrophil

Publications for Severe Cutaneous Adverse Reaction

Articles related to Severe Cutaneous Adverse Reaction:

(show top 50) (show all 1518)
# Title Authors Year
1
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma. ( 30729055 )
2019
2
Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. ( 30782092 )
2019
3
Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome. ( 30737366 )
2019
4
Bronchiolitis Obliterans as long-term sequela of non-drug related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in children. ( 30908698 )
2019
5
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. ( 30612819 )
2019
6
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. ( 30298362 )
2019
7
Serum and blister-fluid elevation and decreased epidermal content of HMGB1 protein in drug-induced Stevens Johnson syndrome/toxic epidermal necrolysis. ( 30613954 )
2019
8
Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing. ( 30623817 )
2019
9
British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people 2018. ( 30829411 )
2019
10
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. ( 30840032 )
2019
11
Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 30872140 )
2019
12
The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. ( 29569740 )
2019
13
A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. ( 29859332 )
2019
14
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis - an Australian analysis of treatment outcomes and mortality. ( 30632424 )
2019
15
Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. ( 30633324 )
2019
16
Lacrimal passage irrigation in children with Stevens-Johnson syndrome or toxic epidermal necrolysis: a five-year retrospective study. ( 30658599 )
2019
17
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. ( 30659711 )
2019
18
Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients with Stevens-Johnson Syndrome. ( 30664843 )
2019
19
A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. ( 30702535 )
2019
20
Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a systemic review. ( 30702955 )
2019
21
Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. ( 30705045 )
2019
22
Multi-Step Grading System for Evaluation of Chronic Ocular Sequelae in Patients with Stevens-Johnson Syndrome. ( 30731084 )
2019
23
Spectrum of gastrointestinal involvement in Stevens - Johnson syndrome. ( 30788030 )
2019
24
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. ( 30809807 )
2019
25
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. ( 30825193 )
2019
26
Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. ( 30830062 )
2019
27
Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. ( 30838038 )
2019
28
Ciprofloxacin-induced Stevens-Johnson Syndrome with Grapefruit Juice Consumption: A Case Report. ( 30868040 )
2019
29
A ten-year retrospective cohort study of the management of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in a New South Wales State Referral Hospital from 2006 to 2016. ( 30908601 )
2019
30
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. ( 29528923 )
2018
31
Notice of Retraction and Replacement: "Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome" (Drayer SM, Laufer LR, Farrell ME). ( 29533269 )
2018
32
Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome. ( 29528935 )
2018
33
Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. ( 29387760 )
2018
34
Severe Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome-beyond skin involvement. ( 29159901 )
2018
35
First case of Stevens-Johnson syndrome after rabies vaccination. ( 29333656 )
2018
36
Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. ( 28689166 )
2018
37
The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. ( 29076187 )
2018
38
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. ( 29387340 )
2018
39
Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. ( 29029855 )
2018
40
Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: A case series. ( 29573443 )
2018
41
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. ( 30541717 )
2018
42
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. ( 29952288 )
2018
43
Anesthetic considerations in Stevens-Johnson syndrome with epilepsy for bilateral amniotic membrane grafting in eye. ( 30078868 )
2018
44
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. ( 30301570 )
2018
45
Corneal limbal stem cell deficiency in children with Stevens-Johnson syndrome. ( 30347185 )
2018
46
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. ( 29912772 )
2018
47
Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. ( 30282109 )
2018
48
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. ( 29176400 )
2018
49
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib. ( 29328518 )
2018
50
Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept. ( 29421925 )
2018

Variations for Severe Cutaneous Adverse Reaction

ClinVar genetic disease variations for Severe Cutaneous Adverse Reaction:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B*15: 02 undetermined variant risk factor
2 HLA-B HLA-B, HLA-B*5801 undetermined variant risk factor
3 HLA-A NM_001242758.1(HLA-A): c.776delC (p.Pro259Leufs) deletion not provided rs1554115495 GRCh38 Chromosome 6, 29944278: 29944278

Expression for Severe Cutaneous Adverse Reaction

Search GEO for disease gene expression data for Severe Cutaneous Adverse Reaction.

Pathways for Severe Cutaneous Adverse Reaction

Pathways related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 FAS FASLG HLA-A HLA-B HLA-C
2
Show member pathways
12.66 FAS FASLG HLA-A HLA-B HLA-C HSPG2
3
Show member pathways
12.31 FAS FASLG HLA-A HLA-B HLA-C
4
Show member pathways
12.3 FAS FASLG GNLY GZMB HLA-A HLA-B
5 12.28 FAS FASLG GZMB IKZF1 NFKBIZ
6
Show member pathways
12.24 FAS FASLG GZMB PRF1
7
Show member pathways
11.97 FAS FASLG GZMB PRF1
8 11.82 HLA-A HLA-B HLA-C
9
Show member pathways
11.72 FASLG GZMB HLA-A
10
Show member pathways
11.64 FAS FASLG GZMB HLA-A HLA-B HLA-C
11
Show member pathways
11.56 FAS FASLG PRF1
12
Show member pathways
11.24 FASLG GZMB HLA-A PRF1
13 10.83 HLA-A HLA-B HLA-C

GO Terms for Severe Cutaneous Adverse Reaction

Cellular components related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 FAS FASLG HLA-A HLA-B HLA-C
2 recycling endosome membrane GO:0055038 9.54 HLA-A HLA-B HLA-C
3 phagocytic vesicle membrane GO:0030670 9.5 HLA-A HLA-B HLA-C
4 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C
5 cytolytic granule GO:0044194 9.16 GNLY PRF1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-C
7 MHC class I protein complex GO:0042612 8.8 HLA-A HLA-B HLA-C
8 extracellular exosome GO:0070062 10.03 FAS FASLG HLA-A HLA-B HLA-C HSPG2

Biological processes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 FAS FASLG HLA-A HLA-B HLA-C
2 interferon-gamma-mediated signaling pathway GO:0060333 9.65 HLA-A HLA-B HLA-C
3 type I interferon signaling pathway GO:0060337 9.63 HLA-A HLA-B HLA-C
4 antigen processing and presentation GO:0019882 9.54 HLA-A HLA-B HLA-C
5 cytolysis GO:0019835 9.52 GZMB PRF1
6 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.51 FAS FASLG
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.5 HLA-A HLA-B HLA-C
8 necroptotic signaling pathway GO:0097527 9.43 FAS FASLG
9 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.43 HLA-A HLA-B HLA-C
10 protection from natural killer cell mediated cytotoxicity GO:0042270 9.4 HLA-A HLA-B
11 positive regulation of T cell mediated cytotoxicity GO:0001916 9.33 HLA-A HLA-B HLA-C
12 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.13 HLA-A HLA-B HLA-C
13 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 8.8 HLA-A HLA-B HLA-C

Molecular functions related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-C

Sources for Severe Cutaneous Adverse Reaction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....